This research develops targeted radiopharmaceutical therapies for HER2-positive cancers. By attaching radioactive isotopes to trastuzumab, treatment delivers precise radiation to cancer cells, overcoming drug resistance. The work includes creating practical drug kits and aims to improve cancer outcomes by replacing non-specific therapies with highly accurate, targeted interventions.

This research investigates how cells repair dangerous DNA double-strand breaks through the non-homologous end joining pathway. By identifying key proteins involved in this error-prone repair process, the work reveals new opportunities to sensitise cancer cells to radiation and chemotherapy, potentially improving treatment outcomes for aggressive cancers.